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a b s t r a c t
Preeclampsia is a pregnancy-speciﬁc condition affecting 2–7% of women and a leading cause of perinatal and
maternal morbidity and mortality. Deﬁciencies of speciﬁc micronutrient antioxidant activities associated with
copper, selenium, zinc, and manganese have previously been linked to preeclampsia at the time of disease. Our
aims were to investigate whether maternal plasma micronutrient concentrations and related antioxidant
enzyme activities are altered before preeclampsia onset and to examine the dependence on genetic variations
in these antioxidant enzymes. Predisease plasma samples (1571 weeks' gestation) were obtained from
women enrolled in the international Screening for Pregnancy Endpoints (SCOPE) study who subsequently
developed preeclampsia (n¼244) and from age- and BMI-matched normotensive controls (n¼472). Micro-
nutrient concentrations were measured by inductively coupled plasma mass spectrometry; associated
antioxidant enzyme activities, selenoprotein-P, ceruloplasmin concentration and activity, antioxidant capacity,
and markers of oxidative stress were measured by colorimetric assays. Sixty-four tag–single-nucleotide
polymorphisms (SNPs) within genes encoding the antioxidant enzymes and selenoprotein-P were genotyped
using allele-speciﬁc competitive PCR. Plasma copper and ceruloplasmin concentrations were modestly but
signiﬁcantly elevated in women who subsequently developed preeclampsia (both Po0.001) compared to
controls (median (IQR), copper, 1957.4 (1787, 2177.5) vs 1850.0 (1663.5, 2051.5) mg/L; ceruloplasmin, 2.5
(1.4, 3.2) vs 2.2 (1.2, 3.0) mg/ml). There were no differences in other micronutrients or enzymes between
groups. No relationship was observed between genotype for SNPs and antioxidant enzyme activity. This
analysis of a prospective cohort study reports maternal micronutrient concentrations in combination with
associated antioxidant enzymes and SNPs in their encoding genes in women at 15 weeks' gestation that
subsequently developed preeclampsia. The modest elevation in copper may contribute to oxidative stress, later
in pregnancy, in those women that go on to develop preeclampsia. The lack of evidence to support the
hypothesis that functional SNPs inﬂuence antioxidant enzyme activity in pregnant women argues against a
role for these genes in the etiology of preeclampsia.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introductiuon
Preeclampsia is a hypertensive condition affecting 2–7% of
pregnant women and is associated with maternal multiorgan
dysfunction. This disease, which manifests as high blood pressure
and proteinuria, is probably mediated by endothelial damage and
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may affect multiple systems of the body and contribute to
adverse pregnancy outcomes including maternal death, preterm
birth, fetal growth restriction, and fetal death [1]. The etiology
remains unknown, but placental defects and oxidative stress
have been implicated and have been reported to develop at early
gestation in affected pregnancies [2,3]. Several dietary micronu-
trients and in particular selenium, which plays a critical role in
antioxidant defense, have been proposed to play a contributory
role [4]. Dietary selenium intake in the United Kingdom, as in
some other European countries, is below the recommended
nutrient intake (60 mg/day for women) [5] and associations
between lower blood selenium concentration and preeclampsia
at delivery [6,7] have been reported. Selenium-dependent glu-
tathione peroxidases (GPx's), which play a key role in protection
against oxidative damage [5,8], have been shown to have reduced
activity during pregnancy, with the lowest activity at delivery
[7,9,10]. In addition, in women with preeclampsia, total GPx
activity seems compromised, because we have reported a reduc-
tion in maternal and fetal activity and placental protein expres-
sion/activity of GPx at the time of delivery compared with
controls [7]. Activity of the selenoproteins is determined by
activity/translation of the relevant genes, among which a number
of single-nucleotide polymorphisms (SNPs) are described in
nonpregnant subjects, including some with reported effects on
gene expression, mRNA translation, or protein stability [11–13].
Preeclampsia has a familial component [14–19], but it is not
known whether these SNPs could, independently or in associa-
tion with lower selenium status, be determinants of the putative
impairment in antioxidant defense.
An increase in the plasma copper concentration has also
been reported in women with established preeclampsia and this
may generate oxidative stress by catalyzing the synthesis of
reactive oxygen species (ROS) [20,21]. In addition, abnormally
high serum ceruloplasmin concentrations in preeclampsia at
delivery have been observed (approximately 96% of plasma
copper is bound to ceruloplasmin) [22]. Lower plasma concen-
trations of zinc [21,23] and placental mRNA expression of
copper/zinc superoxide dismutase (Cu/Zn SOD), as well as
inadequate manganese status, have also been recorded in
affected women [24,25]. Cu/Zn SOD, the cytosolic form of the
enzyme, and mitochondrial manganese SOD (Mn SOD) provide
important antioxidant defense [26], and lower plasma SOD
concentrations have also been linked with preeclampsia [27–29].
The genotypes of SNPs in genes encoding Mn and Cu/Zn SOD
[30,31] have been assessed in two studies, but with contradictory
results [32,33], and lower plasma catalase activity has also been
previously noted in preeclamptic women, after clinical diagnosis
[21,28,29].
Nutrigenomics aims to reveal relationships between nutrition
and the genome, allowing investigation of how genetic factors can
inﬂuence nutritional requirements. It is likely that interactions
between genotype and diet are important in determining the risk
of common complex diseases [34,35], such as preeclampsia.
Nutrients can interact with the genome and with SNPs to mod-
ulate disease risk such as cancer and cardiovascular disease, and
SNPs in genes coding for antioxidant enzymes have been linked to
cancer development [35–37].
We have therefore undertaken a study in a well-characterized
prospective cohort of pregnant women to address (a) the hypoth-
esis that inadequate antioxidant defenses contribute to the gen-
eration of oxidative stress in women before the development of
preeclampsia and (b) whether this is confounded by suboptimal
micronutrient status and (c) whether relationships between
micronutrient status and antioxidant enzyme activities in preg-
nant women may be inﬂuenced by genetic variants affecting the
function of the antioxidant enzymes.
Materials and methods
Participants
This was a nested preeclampsia case–control study of partici-
pants in the SCOPE (Screening for Pregnancy Endpoints; www.
scopestudy.net) study, an international multicenter prospective
cohort study of nulliparous singleton pregnancies with the aim of
developing predictive screening tests for preeclampsia, preterm
birth (PTB), and small-for-gestational-age (SGA) infants. Eligible
women were recruited to the study between November 2004 and
February 2011 at centers in Auckland, Adelaide, Leeds, London,
Manchester, and Cork. Women were excluded if they were judged
to be at high risk for preeclampsia, PTB, or SGA owing to under-
lying medical conditions, preexisting hypertension, or more than
three previous miscarriages or terminations and those undergoing
interventions that may affect pregnancy outcome, as previously
described [38,39]. All participants provided informed written
consent under ethical approval granted from local ethics commit-
tees (New Zealand AKX/02/00/364; Australia REC 1712/5/2008;
London, Leeds, and Manchester 06/MRE01/98; and Cork ECM5(10)
05/02/08).
Samples and clinical data
Nonfasting heparinized plasma samples were selected from
white women recruited at 1571 weeks' gestation: 244 women
who developed preeclampsia and 472 controls were matched for
BMI and age (Table 1 & 2). Women were considered to have a
normal pregnancy outcome if they remained normotensive
(o140 mm Hg systolic blood pressure (sBP) and/or o90 mm Hg
diastolic blood pressure (dBP) before labor), showed no protei-
nuria, delivered a live baby after 37 weeks' gestation who was not
SGA, and had no other signs of pregnancy-related complications.
Deﬁnition of preeclampsia was blood pressure measurements, at
least 4 h apart, after 20 weeks' gestation and before the onset of
labor, in which sBP was Z140 mm Hg and/or dBP was Z90 mm
Hg (Korotkoff V) plus proteinuria (Z300 mg per 24 h or spot urine
protein:creatinine ratio Z30 mg mmol1 creatinine or urine dip-
stick protein Zþþ). For additional analysis, cases were subdivided
into severe preeclampsia (sBP 4160 or dBP 4110 mm Hg), mild
preeclampsia (sBP 140–160 and dBP 90–110 mm Hg), and also
early- (delivery o34 weeks) and late-onset (delivery Z34 weeks)
groups. Relevant clinical data were extracted from the SCOPE
database; biochemical analyses were conducted on heparinized
plasma; DNA for genotyping was extracted from buffy coat samples.
Laboratory investigations
All biochemical analyses were carried out in triplicate, unless
otherwise stated, with standard curves calculated using four-
parameter logistic curve analysis using GraphPad Prism 5 (San Diego,
CA, USA).
Micronutrient concentrations
Plasma concentrations of copper, zinc, selenium, and manga-
nese were assayed by inductively coupled plasma mass spectro-
metry (ICP–MS) at m/z 65, 66, 78, and 55, respectively, as
previously described [40]. Samples and standards (SPEX Certiprep,
Inc.) were prepared identically in a diluent containing 0.1% Triton
X-100 nonionic surfactant (þantifoam-B, Sigma), 2% methanol,
and 1% HNO3 (trace analysis grade), including the internal ICP–MS
standards iridium (5 mg/L), rhodium (10 mg/L), gallium (25 mg/L),
and scandium (50 mg/L). For all analytes, the ICP–MS was run
in collision-reaction cell mode with pure H2 as the cell gas
to maximize sensitivity for 78Se determination. Aspiration was
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through a single sample line via a Burgener–Miramist PEEK
nebulizer. Calibrations for all micronutrients were in the range
0–50 mg/L. Quality of analysis was ensured by the use of appro-
priate reference materials (Seronorm and UTAK; Nycomed Pharma
AS). Trace-element-free techniques were used during collection
and analysis, following guidelines from the International Zinc
Nutrition Consultative Group. Both intra- and interassay coefﬁ-
cients of variation were o5%.
Selenoprotein P
Plasma selenoprotein P concentrations were measured essen-
tially as described previously [41]. Brieﬂy, an immunolumino-
metric sandwich assay (Selenotest, ICI GmbH, Berlin, Germany)
using two monoclonal mouse anti-human selenoprotein P anti-
bodies was used. The analytical detection limit was 0.008 mg/L
and the assay was linear on dilution. The inter- and intra-assay
coefﬁcients of variation were 7.5 and 2%, respectively.
Ceruloplasmin (activity)
Ceruloplasmin activity was assessed in plasma diluted 1:50,
using a commercially available kit following the manufacturer's
protocol (DetectX Ceruloplasmin Colorimetric Activity Kit K035-H1,
Arbor Assays, Ann Arbor, MI, USA). The inter- and intra-assay
coefﬁcients of variation were 22.2 and 3.9%, respectively.
Ceruloplasmin (concentration)
Ceruloplasmin protein concentrations were measured using a
competitive enzyme-linked immunoabsorbent assay (ELISA) as
per the manufacturer's instructions (AssayMax Human Cerulo-
plasmin ELISA Kit EC4001–1, Assaypro LLC, St. Charles, MO, USA).
Plasma samples were diluted 1:100 and analyzed in duplicate. The
standards and plasma samples were added to plates precoated
with a polyclonal antibody speciﬁc for human ceruloplasmin. The
ceruloplasmin present in the samples competed with biotinylated
ceruloplasmin sandwiched by the immobilized polyclonal anti-
body and streptavidin–peroxidase conjugate. The addition of
tetramethylbenzidine, a peroxidase enzyme substrate, instigated
a color development that was stopped with hydrochloric acid after
10 min. The optical density was subsequently measured at
450 nm; inter- and intra-assay coefﬁcients of variation were
8.4 and 1.3%, respectively.
Glutathione peroxidase activity
GPx activity was measured using a commercially available kit,
following the published instructions (Cayman Chemicals, Ann
Arbor, MI, USA). Plasma samples were diluted 1:5 and analyzed
in duplicate. Change in optical density (at 340 nm) was deter-
mined over a 6-min period and the baseline subtracted to
calculate the rate of enzyme activity. The inter- and intra-assay
coefﬁcients of variation were 18.6 and 9.4%, respectively.
Genotyping
DNA was extracted from buffy coat samples by LGC Genomics
(formerly KBioscience, Hertfordshire, UK), using KlearGene chem-
istry (DNA-binding and elution method followed by ethanol
precipitation). Fourteen genes encoding antioxidant enzymes were
selected for genotyping (Table 3). TagSNPs were identiﬁed using
Tagger software applied to data from the HapMapII-CEU popula-
tion of northern and western European ancestry, using a minor
allele frequency of 40.1 and r2480%. Nonsynonymous SNPs with
a reported minor allele frequency of Z0.03 were also included in
the genotyping strategy. Genotyping was performed by LGC
Genomics, with the use of their proprietary ﬂuorescence-based
competitive allele-speciﬁc PCR genotyping assay, KASP. As quality
assurance measures, 15% of samples were assayed in duplicate;
DNA-free negative controls were included in each 96-sample
plate; samples that failed more than 10% of genotyping assays
were excluded from the genotyping study. Further quality control
measures included checks for deviations from Hardy–Weinberg
equilibrium using a χ2 goodness-of-ﬁt statistic and comparison of
interplate allele frequencies.
Thiobarbituric acid-reactive substances (TBARS)
The measurement of TBARS is a well-established method for
monitoring lipid peroxidation utilizing the reaction between mal-
ondialdehyde (MDA), a product of lipid peroxidation, and thiobar-
bituric acid (TBA) at high temperatures of 90–100 1C. The MDA–TBA
product formed is measured colorimetrically at 530–540 nm.
Plasma samples were assayed using a commercial kit (Cayman
Chemicals 10009055) according to a modiﬁed version of the
manufacturer's protocol. After the reaction at high temperature,
the vials were centrifuged for 15–20 min, longer than the recom-
mended time and at room temperature rather than 4 1C: this
minimized cloudiness in the samples, which interfered with the
optical density assessments. The inter- and intra-assay coefﬁcients
of variation were 11.4 and 2.1%, respectively.
Ferric-reducing ability of plasma (FRAP)
The ferric-reducing ability of plasma was measured using a
commercially available kit developed on the Benzie & Strain assay
[42], according to the manufacturer's protocol (DetectX FRAP
colorimetric detection assay K043-H1, Arbor Assays). At low pH a
ferric–tripyridyltriazine complex is reduced to the ferrous (FeII)
form provided a reductant (antioxidant) is present. In the FRAP
assay, excess FeIII is used so that the rate-limiting factor of the
production of the FeII form of the complex is the reducing ability of
the plasma sample. The workable assay range was 31.25–1000 mM
and the plasma samples were assayed at a dilution of 1:2. In our
laboratory, the inter- and intra-assay coefﬁcients of variation were
9.3 and 4.3%, respectively.
Superoxide dismutase
Plasma SOD activity was measured using a commercially avail-
able kit, following the manufacturer's protocol for plasma samples
(DetectX SOD Colorimetric Activity Kit K028-H1, Arbor Assays).
Samples were assayed at a dilution of 1:5. The inter- and intra-assay
coefﬁcients of variation were 22.6 and 1.7%, respectively.
Catalase
Plasma catalase activity was measured using a commercially
available kit, following the manufacturer's protocol (DetectX
Catalase Colorimetric Activity Kit K033-H1, Arbor Assays). Samples
were diluted 1:20 and analyzed in triplicate. The inter- and intra-
assay coefﬁcients of variation were 15.7 and 3.4%, respectively.
Power calculations
Micronutrient status
The number of samples used in this study provided 94% power
to detect a difference of 0.4 standard deviations between cases and
controls with an α¼0.0005.
SNP analysis
Statistical power for assessment of the relationships between
SNPs and relevant enzyme activity was estimated using Quanto
beta version 0.5.5. Using our previous pregnancy data [7] on GPx
activity (mean 50710 nmol/min/ml) and selenium (mean
58.4714.9 mg/L) in an additive model for minor allele frequencies
between 0.1 and 0.5 the study had 82% power to detect a
difference in allelic expression that accounts for 4% or more of
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the total variation in the 472 controls, equivalent to a change of
0.3 to 0.5 nmol/min/ml per minor allele for GPx activity, 4 to 7 mg/L
for selenium. The Bonferroni correction for testing of multiple
SNPs was applied to the power calculations, using α¼0.0005; this
is a conservative adjustment in the light of the lack of indepen-
dence between nearby SNPs, owing to linkage disequilibrium;
moreover only 69 SNPs were in fact considered.
Statistical analyses
All statistical analysis was carried out in Stata version 11.2
(StataCorp, College Station, TX, USA) and the diagt package [43].
Data were checked for normality of distribution using appropriate
distributional plots, and Box-Cox regression was used to deter-
mine optimal transformations where needed [44,45]. Summary
data are presented as median (quartiles) or n (%) as appropriate.
Between-group comparisons were made using Mann–Whitney
U tests. Spearman's rank correlation test was used to test associa-
tions. SNP genotypes were coded 0, 1, or 2 dependent on the
number of minor alleles, and genetic association with relevant
enzyme activities was tested by linear regression analysis under an
additive model in control and case samples separately (Table 4).
A formal Bonferroni correction to the P values for multiple
testing was not used for interpretation of the results of micro-
nutrient analyses, as the number of tests required for adjustment
is a matter of opinion. Instead, the level of multiple testing, the
coherent pattern of results, and the level of signiﬁcance were
borne in mind when considering how to interpret related results.
Conﬁdence intervals (95%) are given where appropriate [46,47].
Results
Subjects
The characteristics of 244 women who developed preeclampsia
and 472 controls recruited at 1571 weeks' gestation are shown in
Table 1; infant outcomes are shown in Table 2; the two groups
were matched for age and BMI.
Genetic analysis
Fourteen genes were selected for genotyping, focusing on
antioxidant enzymes and metalloproteins. Individuals were geno-
typed for 69 SNPs. Assay design was unsuccessful for 4 SNPs
(rs8136921 in TXN2, rs1050450 in GPX1, rs4958872 in GPX3,
rs4713167 in GPX6), and genotypes of rs480496 in the catalase
gene deviated signiﬁcantly from Hardy–Weinberg equilibrium;
these 5 SNPs were excluded from further investigation. The
genotyping success rate was over 97.5% for all the remaining 64
SNPs; allele frequencies in cases and controls are shown in Table 3.
Ten subjects in whom genotyping was unsuccessful in 5 or more
SNPs were excluded from further analysis of all genetic data.
Table 1
Characteristics at booking, at enrollment, and after onset of preeclampsia.
Parameter Normotensive controls (n¼472) Preeclampsia (n¼244)
Maternal age (years) 29 [23, 32] 28 [23, 32]
Booking body mass index (kg/m2) 25.4 [22.9, 29.4] 26.3 [23.2, 31.1]
Highest ﬁrst-trimester systolic BP (mm Hg) 107 [100, 112] 111 [104.8, 120]
Highest ﬁrst-trimester diastolic BP (mm Hg) 63 [60, 69] 69 [63.5, 74]
Current smoker 58 (12) 24 (10)
Quit smoking 81 (17) 34 (14)
Never smoked 333 (71) 186 (76)
Gestational age at enrollment, weeks 15 [15, 16] 15 [14, 16]
After clinical diagnosis
Highest systolic BP 120 [115, 130] 150 [145, 162]n
Highest diastolic BP 74 [70, 80] 98 [92, 104]n
Dipstick proteinuria
Not done 258 (55) 142 (58)
Negative 214 (45) —
Present 1þ or greater — 102 (42)
Protein creatinine ratio (mg/mmol) — 94 [46, 214] (n¼84)
Early-onset preeclampsia — 38 (15.6)
Severe preeclampsia — 116 (47.5)
Data are presented as median [IQR] or number (percentage). Deﬁnitions: severe preeclampsia, sBP 4160 or dBP 4110 mm Hg; mild
preeclampsia, sBP 140–160 and dBP 90–110 mm Hg; early onset, delivery o34 weeks; and late onset, delivery Z34 weeks. Mann–Whitney
U test was used for between-group comparisons.
n Po0.0001 for BP (blood pressure).
Table 2
Characteristics at delivery for women in each group.
Parameter Normotensive controls (n¼472) Preeclampsia (n¼244)
Gestation at delivery, weeks 40 [39,41] 38 [37,40]
Preterm delivery o37/40 weeks 0 34 (15.2)
Birth weight, g 3600 [3328,3866] 3190 [2570,3565]n
SGA (o10th customized birth weight centile) 0 61 (25)
Data are presented as the median [IQR] or number (percentage). SGA, small for gestational age. Mann–Whitney U test was used for between-
group comparisons.
n Po0.0001.
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Table 3
SNPs used to genotype.
Gene SNP Major/minor allele Type MAF controls MAF cases P valuea
SOD1 rs10432782 T/G Intron 0.13 0.11 0.51
SOD1 rs1041740 C/T Intron 0.29 0.30 0.93
SOD1 rs2234694 A/C Intron 0.04 0.05 0.80
SOD2 rs2855116 A/C 30UTR 0.48 0.47 0.94
SOD2 rs5746136 C/T 30UTR 0.31 0.30 0.79
SOD2 rs7855 A/G 30UTR 0.04 0.05 0.86
SOD2 rs4880 A/G Missense 0.49 0.49 0.92
SOD3 rs2536512 G/A Missense 0.36 0.35 0.87
SOD3 rs1799895 C/G Missense 0.01 0.01 0.18
CAT rs2284365 T/C Intron 0.21 0.19 0.07
CAT rs533425 G/A Intron 0.39 0.40 0.84
CAT rs12270780 G/A Intron 0.28 0.28 0.72
CAT rs11032700 A/C Intron 0.33 0.35 0.83
CAT rs480496 G/A Intron Excluded—not in HWE
CAT rs10488736 C/T Intron 0.31 0.32 0.67
CAT rs11032703 C/T Intron 0.13 0.09 0.08
CAT rs1001179 C/T 50FR 0.21 0.22 0.81
CAT rs566979 A/C Intron 0.37 0.40 0.59
CAT rs480575 A/G Intron 0.28 0.28 0.21
TXN rs4135187 A/T Intron 0.09 0.11 0.32
TXN rs4135179 T/C Intron 0.23 0.19 0.21
TXN rs4135203 C/G Intron 0.21 0.22 0.29
TXN rs4135225 A/G Intron 0.33 0.34 0.86
TXN rs4135221 G/A NCE 0.12 0.11 0.70
TXN rs1410051 T/C Intron 0.22 0.21 0.34
TXN rs4135192 A/G Intron 0.31 0.30 0.95
TXN rs4135208 A/G Intron 0.32 0.33 0.65
TXN rs4135168 T/C Intron 0.24 0.25 0.19
TXN rs4135165 G/A Intron 0.08 0.08 0.79
TXN rs4135215 T/C Intron 0.15 0.16 0.91
TXN rs4135220 T/G NCE 0.47 0.48 0.24
TXN rs2418076 C/T Intron 0.26 0.26 0.84
TXN rs4135212 C/T Intron 0.14 0.14 0.13
TXN rs4135218 T/C NCE 0.45 0.44 0.64
TXN2 rs8136921 T/C Intron Failed assay design
TXN2 rs9622400 T/C Intron 0.09 0.10 0.95
TXN2 rs2267337 C/T Intron 0.18 0.20 0.68
TXN2 rs6519008 A/C Intron 0.09 0.09 0.49
TXN2 rs8139906 G/C Intron 0.17 0.17 0.46
TXN2 rs5756202 A/C Intron 0.15 0.14 0.59
SEPP1 rs7579 C/T 30UTR 0.27 0.30 0.48
SEPP1 rs3877899 C/T Missense 0.24 0.22 0.54
SEPP1 rs230819 C/A NCE 0.46 0.45 0.91
SEPP1 rs13168440 T/C Intron 0.16 0.14 0.53
GPX1 rs1050450 G/A Missense Failed assay design
GPX1 rs1800668 G/A 50UTR 0.30 0.32 0.46
GPX1 rs8179169 C/G Missense Nonpolymorphic
GPX2 rs2412065 C/G Intron 0.19 0.21 0.60
GPX2 rs2737844 G/A Intron 0.28 0.31 0.53
GPX2 rs17880492 G/A Missense Nonpolymorphic
GPX3 rs4958434 G/A Intron 0.17 0.16 0.60
GPX3 rs8177431 A/G Intron 0.37 0.29 0.007
GPX3 rs4958872 T/C Intron Failed assay design
GPX3 rs3763011 G/A Intron 0.21 0.13 0.001
GPX3 rs2070593 G/A 30UTR 0.19 0.13 0.01
GPX4 rs713041 C/T Missense 0.44 0.42 0.70
GPX5 rs2273106 A/G Intron 0.09 0.08 0.85
GPX5 rs440481 A/C Intron 0.17 0.15 0.39
GPX5 rs445870 A/G Intron 0.30 0.29 0.88
GPX5 rs58554303 T/C Missense 0.02 0.01 0.16
GPX6 rs4713166 C/T Intron 0.09 0.08 0.85
GPX6 rs2859358 T/A Intron 0.18 0.16 0.58
GPX6 rs4713167 T/C Intron Failed assay design
GPX6 rs35394555 C/G Missense o0.01 o0.01 0.77
GPX6 rs35062161 A/T Missense 0.08 0.06 0.24
GPX6 rs406113 A/C Missense 0.31 0.31 0.99
GPX7 rs946154 C/G Intron 0.33 0.35 0.84
GPX7 rs3753753 G/C Intron 0.28 0.28 0.97
GPX7 rs1047635 A/C 30UTR 0.47 0.49 0.60
TagSNPs were genotyped in 14 genes encoding antioxidants and selenoproteins. MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium; 50FR, 50 ﬂanking region;
NCE, noncoding exon.
a P values are shown for case–control comparisons of genotype frequencies using χ2 analysis.
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The genetic component of this study was designed to investi-
gate the effect of genetic variations on the activity of antioxidant
enzymes. There was no association between SNP genotypes in the
relevant genes and the activity of the antioxidant enzymes SOD,
GPx, or catalase; selenoprotein P concentration; or TBARS or FRAP
in cases or controls (P40.05 for all analyses; Table 4).
This study was not designed for case–control analysis of genetic
association, for which considerably larger sample sizes are
required to achieve adequate statistical power. Three SNPs within
GPX3, which display partial linkage disequilibrium with one
another (D0 ¼ 1; r2¼0.3 to 0.9), showed nominal association with
preeclampsia (P¼0.01 to 0.001), but this was not signiﬁcant after
correction for multiple testing.
Micronutrients
The maternal copper concentration was signiﬁcantly (Po0.0001)
higher in the women who later developed preeclampsia, compared
to controls (Table 5). This difference was maintained when copper
concentrations were analyzed in the individual participating coun-
tries, and overall only a small variation between countries and no
signiﬁcant differences were observed. All other micronutrients did
not differ between groups (P40.05; Table 5). No additional differ-
ences were observed in micronutrient concentrations between either
mild or severe/early or late onset preeclampsia (P40.05 for all).
Biochemical measurements
Ceruloplasmin concentrations were signiﬁcantly increased in
the women who subsequently developed preeclampsia compared
with controls (P¼0.02; Table 5), whereas ceruloplasmin activity
did not differ between groups. We measured TBARS as an indirect
marker of oxidative stress via lipid peroxidation and FRAP to
measure antioxidant capacity. There were no differences between
groups in any of the associated antioxidant enzyme activities,
FRAP, or TBARS (P40.05 for all; Table 5). No additional differences
were observed between either mild or severe/early or late onset
preeclampsia (P40.05 for all).
Signiﬁcant positive correlations were observed between copper
and both ceruloplasmin activity (r¼0.24, Po0.0001) and cerulo-
plasmin concentration (r¼0.16, Po0.0001). Copper and cerulo-
plasmin concentrations were positively associated with TBARS
concentrations (r¼0.15, P o 0.0001; r¼0.39, Po0.0001, respec-
tively). In addition, signiﬁcant associations were also found bet-
ween plasma selenium status and both GPx activity (r¼0.12,
P¼0.005) and selenoprotein P concentration (r¼0.53, Po0.0001).
Discussion
To our knowledge, this study is the ﬁrst to report maternal
plasma micronutrient concentrations in combination with asso-
ciated antioxidant enzymes and markers of both antioxidant
capacity and oxidative stress in women at 15 weeks' gestation
who subsequently developed preeclampsia. Although many of the
measured micronutrients, and associated enzyme activities, parti-
cularly selenium and GPx, have been shown to be reduced in
women with established preeclampsia at time of delivery [5,7], we
found no evidence of this in predisease samples. This observation
suggests that the reduced selenium concentration and GPx activity
and increased oxidative stress at delivery may be a consequence of
the oxidative stress associated with preeclampsia, rather than a
cause. Therefore this ﬁnding does not support the suggestion that
supplementation with these micronutrients could help prevent
the development of preeclampsia, which has its origins early in
pregnancy.
The genetic component of this study was designed to assess the
inﬂuence of SNPs on markers of plasma antioxidant activity at
1571 weeks' gestation, using a comprehensive tag-genotyping
strategy. In contrast to some previous reports (discussed below)
this study, which was powered to detect a genetic effect account-
ing for 4% of variation in target antioxidant markers in controls,
did not identify any associations with genotype.
In a nonpregnant population, a study of two of the four SNPs in
SEPP1, which were also included in the present study (rs7579 in
Table 4
Genetic variants tested for association with antioxidant markers.
Gene Marker Modiﬁer
SOD1–3 SOD activity Copper, zinc, manganese
GPX1–7 GPx activity Selenium
CAT Catalase activity
SEPP1 Selenoprotein P concentration Selenium; BMI
All genes TBARS
All genes FRAP
Genetic associations were tested separately in case and control groups by regression
analysis of measures of antioxidant activity against genotype, with and without
adjustment for modifying factors; P40.05 for all analyses. CAT, catalase; SOD, super-
oxide dismutase; GPx, glutathione peroxidase; TBARS, thiobarbituric acid-reactive
substances; FRAP, ferric-reducing ability of plasma; BMI, body mass index.
Table 5
Maternal plasma micronutrient concentrations, antioxidant activities, and associated concentrations in women who had a healthy pregnancy and those who developed
preeclampsia.
Micronutrient/biochemical measurement Normotensive controls (n¼472) (median [IQR]) Preeclampsia (n¼244) (median [IQR])
Selenium concentration (mg/L) 79.6 [73.1, 86.8] 79.0 [71.8, 87.4]
Copper concentration (mg/L) 1850.0 [1663.5, 2051.5] 1957.4 [1787, 2177.5]nn
Zinc concentration (mg/L) 575.7 [515.6, 641.7] 579.6 [521.1, 638.6]
Manganese concentration (mg/L) 1.4 [0.7, 1.7] 1.4 [1.0, 1.7]
Ceruloplasmin activity (U/ml) 158.6 [133.5, 184.5] 162.3 [132.4, 187.1]
Ceruloplasmin concentration (mg/ml) 2.2 [1.2, 3.0] 2.5 [1.4, 3.2]n
Selenoprotein P (mg/ml) 3.4 [3.0, 3.8] 3.4 [3.0, 3.7]
FRAP activity (U/ml) 741.2 [651.6, 848.1] 715.5 [625.6, 822.0]
GPx activity (nmol/min/ml) 45.7 [26.8, 57.2] 43.3 [25.5, 58.8]
Superoxide dismutase activity (U/ml) 0.5 [0.3, 0.6] 0.5 [0.4, 0.6]
Catalase activity (U/ml) 25.4 [19.1, 33.7] 24.8 [19.0, 33.8]
TBARS (mM) 6.7 [5.6, 9.2] 6.5 [5.4, 8.3]
Data are presented as median [IQR]. GPx, glutathione peroxidase; TBARS, thiobarbituric acid-reactive substances; FRAP, ferric-reducing ability of plasma. Mann–Whitney
U test was used for between-group comparisons.
n Po0.05.
nn Po0.001.
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the 30UTR and the missense SNP rs3877899), reported a signiﬁcant
interaction between genotype, gender, and BMI, affecting plasma
selenium and selenoprotein P concentrations and the activity of
the selenoenzymes GPx1, GPx3, GPx4, and thioredoxin [48]. The
interactive effects of SEPP1 genotype and BMI were most evident
after selenium supplementation, suggesting that the effects of
genotype may be modiﬁed by nutritional status. A further study of
four tagSNPs in SEPP1 showed that baseline plasma selenium and
genotype were not associated [49], although there is evidence that
the relative abundance of the two isoforms of selenoprotein P at
baseline are inﬂuenced by genotype [50]. In the present study,
plasma selenium, selenoprotein P, and GPx activity were signiﬁ-
cantly correlated, as in the nonpregnant state, but SEPP1 genotype
was not associated with any of these markers, either alone or after
adjustment for BMI (data not shown). Plasma selenium concen-
trations are low in normal pregnancy, suggesting that the opera-
tion of regulatory factors, including nutritional status and plasma
dilution, may mask the effect of SEPP genotype in pregnancy.
For completeness, genotyping covering all SNPs in the GPX1–7
genes was undertaken as part of this study, although GPx5 and
GPx7 are not selenoproteins. GPx activity in plasma, which is
predominantly due to GPx3 expression, was not associated with
genotype for SNPs in any of the GPX genes tested. After their
ﬁnding of an association between two intronic SNPs in GPX3 and
gastric cancer, Wang et al. conducted reporter gene studies that
supported functional effects of these SNPs on transcriptional
expression [51]. SNP rs4958872, which is a perfect proxy for one
of these intronic SNPs, failed assay design in the present study, but
it is partially captured by rs4958434 and rs8177431 (D0 ¼1;
r2¼0.75), which showed no evidence of association with plasma
GPx activity. Associations between SNP genotypes in GPX1 and
GPX4 and GPx activity measured in erythrocytes or lymphocytes
have been reported in nonpregnant subjects [11–13]. We did not
have access to suitable material for investigation of intracellular
GPx activity, which may have limited our ability to detect SNP-
dependent variability.
This study did not demonstrate any association between
tagSNPs in the three SOD genes encoding soluble Cu/Zn SOD
(SOD1), Mn SOD (SOD2), or extracellular Cu/Zn SOD (SOD3) and
preeclampsia. Polymorphisms within the SOD genes have shown
statistical association in case–control studies with disorders fea-
turing oxidative damage, including cancers and diabetes [52], but
there have been relatively few studies of the functional basis for
these associations. An Ala- Thr missense polymorphism in SOD3
(rs2536512) was associated with preeclampsia complicated by
fetal growth restriction in a relatively small study (159 cases and
114 controls) [33]. This ﬁnding was not replicated in the present
study, nor was there any evidence for an association between
rs2536512 and plasma SOD activity. Decreased expression of Cu/Zn
SOD in trophoblast cells harvested from preeclamptic placentae
has been demonstrated [53]; studies of fetal SOD genotypes would
therefore be of interest.
Reporter gene assays, supported by measurements of catalase
activity in genotyped individuals, have demonstrated that catalase
expression is inﬂuenced by a polymorphism in the 50 ﬂanking
region of the gene (rs1001179), which affects transcription factor
binding [54]. The association of the minor allele at this SNP with
lower red cell catalase activity has been conﬁrmed, and an
interaction with fruit and vegetable consumption has been docu-
mented [55]. In the present study, the lack of association of plasma
catalase with genotype at this or any other tagSNP may be due to
the overriding inﬂuence of the oxidative stress associated with
normal pregnancy or the moderating effects of diet.
The raised copper and ceruloplasmin concentrations in women
who subsequently develop preeclampsia are in accord with reports
of increased copper concentrations in women with preeclampsia at
the time of disease [20,21], suggesting a potential etiological role.
Copper is a component of several metalloenzymes and an essential
cofactor of antioxidant enzymes, but can also act as an oxidant [56].
Fattah et al. reported increased copper concentrations in maternal
blood but not placenta or cord blood in preeclampsia before
delivery, suggesting that the placenta is not the source of the
copper; rather it may be released from other tissues such as the
liver [22].
Ceruloplasmin is known to be an acute-phase reactant, being
stimulated by inﬂammatory cytokines leading to increased serum
concentrations rising during infection, inﬂammation, and tissue
trauma [57]. During pregnancy, plasma copper concentrations
increase owing to induction of ceruloplasmin by estrogen, return-
ing to normal nonpregnant values after delivery [58–60]. In this
cohort, the estrogen concentrations were not available. Because
copper is a redox-active transition metal and can participate in
single-electron reactions and catalyze free radical formation, the
modest elevation in plasma copper observed in the women who
later developed preeclampsia could contribute to oxidative stress
in association with the onset of disease later on in pregnancy [20].
Conversely, the raised copper concentration may also be a protec-
tive response to prevent excessive ROS production and oxidative
stress, via its antioxidant capacity, through the induction of
copper-dependent antioxidant enzymes. Our data are in accor-
dance with previous reports of raised serum ceruloplasmin and
copper in women with established preeclampsia, which, unlike
this study, also showed a correlation with elevated serum TBARS
and prompted the suggestion that synthesis occurred in response
to lipid peroxidation [20,57,61]. The discordance between the
increased ceruloplasmin concentrations and activity in the women
who later developed preeclampsia could reﬂect a disproportionate
increase in copper binding capacity, rather than its secondary role
as a ferroxidase enzyme, as Vitoratos et al. have reported increased
ceruloplasmin concentrations in serum of preeclamptic women,
but no differences in ferroxidase activities [57]. This may indicate
biological dysfunction of the ceruloplasmin molecule. However,
further studies are required to substantiate this hypothesis.
A limitation of the study was its restriction to women of white
European ancestry, to avoid the confounding effects of population
admixture on interpretation of the results of SNP genotyping.
Future studies are required to conﬁrm the increased copper and
ceruloplasmin concentrations in other ethnic groups.
In conclusion, this study reports maternal micronutrient con-
centrations in combination with associated antioxidant enzy-
mes and SNPs in their encoding genes in women at 15 weeks'
gestation that subsequently developed preeclampsia. The modest
elevation in copper may contribute to oxidative stress, later in
pregnancy, in those women that go on to develop preeclampsia.
The lack of evidence to support the hypothesis that functional
SNPs inﬂuence antioxidant enzyme activity in pregnant women
argues against a role for these genes in the etiology of preec-
lampsia.
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